Marshall Wace, LLP Anavex Life Sciences Corp. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $948,302 - $1.36 Million	144,779 Added 1281.34%	156,078 $1.02 Million
Q2 2023 Aug 14, 2023	SELL	$7.66 - $9.5 $278,831 - $345,809	-36,401 Reduced 76.31%	11,299 $91,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $105,697 - $149,272	12,704 Added 36.3%	47,700 $408,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $267,719 - $504,992	34,996 New	34,996 $324,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $2.77 Million - $4.86 Million	378,278 Added 833.98%	423,636 $4.24 Million

Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $441,786 - $802,383	45,358 New	45,358 $558,000
Q2 2021 Aug 13, 2021	SELL	$10.16 - $28.86 $1.66 Million - $4.71 Million	-163,087 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $843,159 - $2.63 Million	163,087 New	163,087 $2.44 Million

159

31.6M

910K

1.35M

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $352M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.